Teva Pharmaceutical (TEVA) Tops Q1 EPS by 2c

Teva Pharmaceutical (NYSE: TEVA) reported Q1 EPS of $1.22, $0.02 better than the analyst estimate of $1.20. Revenue for the quarter came in at $5 billion versus the consensus estimate of $5.11 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins